Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000085.xml
Thorac Cardiovasc Surg 2009; 57: S156-S158
DOI: 10.1055/s-2008-1039252
DOI: 10.1055/s-2008-1039252
DHZB Symposia
© Georg Thieme Verlag KG Stuttgart · New York
Impact of Malignancies on Long-Term Survival after Heart Transplantation
Further Information
Publication History
Publication Date:
30 April 2009 (online)
Introduction
With the development of new immunosuppressive agents, the majority of transplant recipients are surviving for over a decade, and malignancy has become a major burden on long-term survival. An increased risk of malignancy is well described after heart transplantation (HTx) for both solid tumors and lymphoproliferative disease [1].
References
- 1 Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant. 2007; 26 557-564
- 2 Kirklin J K, Naftel D C, Bourge R C, McGiffin D C, Hill J A, Rodeheffer R J, Jaski B E, Hauptman P J, Weston M, White-Williams C. Evolving trends in risk profiles and causes of death after heart transplantation: a ten-year multi-institutional study. J Thorac Cardiovasc Surg. 2003; 125 881-890
- 3 Taylor D O, Edwards L B, Boucek M M, Trulock E P, Aurora P, Christie J, Dobbels F, Rahmel A O, Keck B M, Hertz M I. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant. 2007; 26 769-781
- 4 Lehmkuhl H, Dengler T, Hiemann N, Pethig K, Stempfle U, Wagner F. Working Group “Thoracic Transplantation”/German Society for Cardiology .Malignancy in thoracic transplantation: a German nationwide post-HTx malignancy registry. San Francisco, USA; International Society for Heart and Lungtransplantation 2007
- 5 Potaris K, Radovancevic B, Thomas C D, Gregoric I, Vaporciyan A A, Riggs S A, Radovancevic R, Vaughn W K, Frazier O H. Lung cancer after heart transplantation: a 17-year experience. Ann Thorac Surg. 2005; 79 980-983
- 6 Casadio F, Croci S, D'Errico Grigioni A, Corti B, Grigioni W F, Landuzzi L, Lollini P L. Toward the definition of immunosuppressive regimens with antitumor activity. Transplant Proc. 2005; 37 2144-2147
- 7 O'Neill J O, Edwards L B, Taylor D O. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006; 25 1186-1191
- 8 Ulrich C, Euvrard S, Salasche S, Schmook T. Impact of new immunosuppressants on the dermatological outcome of organ transplant patients. J Am Acad Dermatol March. 2004; 50 (Suppl. 3) P31
- 9 Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004; 4 222-230
- 10 Ippoliti G, Rinaldi M, Pellegrini C, Viganò M. Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol Hematol. 2005; 56 101-113
- 11 Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl H B, Berger F, Hetzer R, Reinke P. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant. 2008; 27 100-105
- 12 Trappe R U, Choquet S, Reinke P, Dreyling M, Mergenthaler H G, Jäger U, Kebelmann-Betzing C, Jonas S, Lehmkuhl H, Anagnostopoulos I, Leblond V, Hetzer R, Dörken B, Riess H, Oertel S. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after upfront chemotherapy: the role of single-agent rituximab. Transplantation. 2007; 84 1708-1712
- 13 Hauptman P J, Mehra M R. It is time to stop ignoring malignancy in heart transplantation: a call to arms. J Heart Lung Transplant. 2005; 24 1111-1113
Dr. med. Hans Brendan Lehmkuhl
DHZB
Augustenburger Platz 1
13353 Berlin
Germany
Phone: + 49 (0) 30 45 93 20 00
Fax: + 49 (0) 30 45 93 21 00
Email: lehmkuhl@dhzb.de